David Theis, MD
Rheumatology · Colorado Springs, CONPI 1104147453
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,261 of the $60,923 with a category attached, or 71.0%. 33 manufacturers reported payments, led by AbbVie at 39.8% of the total. Reporting peaked in 2019 at $45,318 and has fallen 91.3% since, to $3,924 in 2025. Among rheumatology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 781 payments — averaging $78.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- Novartis$21K
- Amgen$9K
- UCB, Inc.$1K
- AstraZeneca$1K
- Pfizer$844
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$43,26171%
- Travel & lodging$3,5016%
- Food & beverage$14,03823%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 241 | $24,227 |
| Novartis | 68 | $21,475 |
| Amgen(2 entities) | 140 | $8,985 |
| UCB, Inc. | 52 | $1,119 |
| AstraZeneca(2 entities) | 48 | $1,038 |
| Pfizer | 64 | $844 |
| GSK | 40 | $547 |
| Johnson & Johnson | 16 | $381 |
| Sobi, Inc | 13 | $349 |
| Sandoz | 12 | $317 |
| Genentech USA, Inc. | 12 | $188 |
| Lilly USA, LLC | 9 | $185 |
| ANI Pharmaceuticals, Inc. | 14 | $182 |
| Actelion Pharmaceuticals US, Inc. | 5 | $122 |
| Mallinckrodt Hospital Products Inc. | 5 | $122 |
| Celltrion USA Inc. | 4 | $104 |
| E.r. Squibb & Sons, L.L.C. | 6 | $101 |
| Boehringer Ingelheim | 4 | $96 |
| Radius Health, Inc. | 4 | $88 |
| Scilex Pharmaceuticals Inc. | 4 | $65 |
| Octapharma USA, Inc. | 3 | $62 |
| Fresenius Kabi USA, LLC | 2 | $44 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Sanofi | 2 | $31 |
| Biocon Biologics Inc | 1 | $25 |
| Organon | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Mylan Institutional Inc. | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,923 in reported general payments places this provider in the 95th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 83 | $647,477 |
| Enbrel SureclickEtanercept | 66 | $533,890 |
| Cosentyx Sensoready PenSecukinumab | 24 | $311,275 |
| Orencia ClickjectAbatacept | 47 | $301,438 |
| Humira(Cf)Adalimumab | 28 | $197,273 |
| RinvoqUpadacitinib | 24 | $164,564 |
| Xeljanz XrTofacitinib Citrate | 13 | $121,964 |
| EnbrelEtanercept | 15 | $115,502 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $114,002 |
| XeljanzTofacitinib Citrate | 20 | $113,789 |
| Humira PenAdalimumab | 15 | $104,666 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 32 | $47,751 |
| Hydroxychloroquine Sulfate | 376 | $11,688 |
| MethotrexateMethotrexate Sodium | 489 | $8,709 |
| Diclofenac Sodium | 14 | $3,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq | $24,227 | $361,83752 claims |
| AmgenEnbrel | $8,985 | $115,50215 claims |
| PfizerXeljanz | $844 | $113,78920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 rheumatology providers in Colorado.
Other rheumatology in Colorado Springs
- Christopher ChongColorado Springs$11K
- Artur KalutaColorado Springs$7K
- Megan MacneilColorado Springs$6K
- Christopher InserraColorado Springs$5K
- Dan CristescuColorado Springs$4K
- Michael SayersColorado Springs$2K
- James LevineGreeley$130K
- Aryeh FischerDenver$114K
- Adam BerlinbergDenver$94K
- Rennie McCabeDenver$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.